flow trial semaglutide ppt Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes Once-Weekly Semaglutide Is Associated With

When compared with controls, the GLP-1 cohort had reduced uveitis risk, and this stayed consistent for those with type 2 diabetes and those without, as well as across different uveitis subtypes

More specifically, data showed that semaglutide decreased the overall likelihood of the following, regardless of the severity of diabetes-related kidney disease: Either serious heart failure for the first time or cardiovascular death, by 27% Heart failure events, by 27% Cardiovascular death, by 29% Positive effects were consistent, regardless of history of heart failure

Presented at ADA 86th Scientific Sessions

How much do GLP-1 weight loss programmes cost in the UK